Business description from prospectus – Beta Drugs is primarily engaged in the manufacturing of oncology products.
Its products range from anticancer tablets, capsules, injections and lyophilized injections. The company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease.
As on March 31, 2017, the company had a portfolio of over 50 products products catering to various oncology diseases including breast, brain, bone, lung, mouth, head & neck, prostate, haematology, cervics, oeaophagus etc.
It has increased its product range, starting from 35 in 2015-16 to 50 active products in 2016-17. The company’s oncology portfolio includes key brands like Admine, Adgef, Addplatin, Erlotad etc.
Promoters of Beta Drugs – Vijay Kumar Batra
Beta Drugs IPO details
|Subscription Dates||29 Sep – 4 Oct 2017|
|IPO Price band||INR85 per share|
|Fresh issue||2,296,000 shares (INR19.52 crore)|
|Offer for sale||Nil|
|Total IPO size||2,296,000 shares (INR19.52 crore)|
|Minimum bid (lot size)||1,600 shares|
|Face Value||INR10 per share|
|Listing On||NSE Emerge SME platform|
|Beta Drugs’ financial performance (in INR lakh)|
|Profit after tax||4.4||2.2||11.4||113.4||517.9|
Beta Drugs Limited
Phone: +91 01795 236196
Earnings Per Share (EPS): INR8.69
Price/Earnings (P/E) ratio: 9.78
Return on Net Worth (RONW): 70.18%
Net Asset Value (NAV): INR12.39 per share
Link Intime India Private Limited
C-101, 247 Park, L.B.S.
Vikhroli (West), Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]
Beta Drugs IPO allotment status is now available on Link Intime’s website.
ONLINE Investors RoadShow OF SME IPO BETA DRUGS LIMITED
Click on this link to get allotment status.
IPO Opening Date: 29 September 2017
IPO Closing Date: 4 October 2017
Finalisation of Basis of Allotment: 9 October 2017
Initiation of refunds: 10 October 2017
Transfer of shares to demat accounts: 11 October 2017
Listing Date: 12 October 2017
Listing Price on NSE SME: INR102 per share (up 20% from IPO price)
Closing Price on NSE SME: INR101.95 per share (up 19.94% from IPO price)